Last reviewed · How we verify
Belviq
At a glance
| Generic name | Belviq |
|---|---|
| Also known as | Lorcaserin |
| Sponsor | Columbia University |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Obesity
Common side effects
Key clinical trials
- Rebalancing the Serotonergic System in Cocaine Dependence (PHASE1)
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (PHASE3)
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Lorcaserin in Obesity: Identification of CNS Targets Using FMRI (PHASE4)
- Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
- Predictors of Lorcaserin-Induced Weight Loss (PHASE4)
- Treatment With Lorcaserin for Cocaine Use: The TLC Study (PHASE2)
- Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Belviq CI brief — competitive landscape report
- Belviq updates RSS · CI watch RSS
- Columbia University portfolio CI